Aridis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Aridis Pharmaceuticals

16/08/2022 13:17

* Aridis Pharmaceuticals Inc  ARDS.OQ  reported a quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 6 cents per share.
    * Revenue rose 784.8% to $292.00 thousand from a year ago;
analysts expected $10.46 million. 
    * Aridis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 87.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aridis Pharmaceuticals Inc shares had risen by 99.1% this
quarter and lost 6.0% so far this year.
    * The company reported a quarterly loss of $7.98 million.
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $11.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 16
at 12:17 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.06          -0.45          Missed
 Mar. 31 2022      -0.51          -0.44          Beat
 Dec. 31 2021      -0.41          -0.92          Missed
 Sep. 30 2021      -0.51          -1.94          Missed